Hirobriz Breezhaler (Indacaterol)

Hirobriz Breezhaler is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients.

• Long‑term bronchodilation to improve airflow and reduce COPD symptom burden.
• Reduction of exacerbation frequency when used regularly.
• Improvement in exercise tolerance and health‑related quality of life.
• Adjunct to inhaled corticosteroids in patients requiring additional bronchodilator support.
• Use in patients who can operate the Breezhaler device effectively.
• Suitable for patients who prefer a dry‑powder inhaler over metered‑dose devices.
• Can be part of a step‑wise COPD treatment algorithm as recommended by European guidelines.

• Indacaterol acts as a selective, long‑acting agonist at β2‑adrenergic receptors on airway smooth‑muscle cells. Binding triggers activation of adenylate cyclase, increasing intracellular cyclic AMP. Elevated cAMP leads to relaxation of bronchial smooth muscle, inhibition of mediator release, and enhanced mucociliary clearance, resulting in sustained bronchodilation over 24 hours. The high receptor affinity and slow dissociation contribute to its once‑daily dosing profile.

Adverse reactions reported with Hirobriz Breezhaler are generally consistent with other long‑acting β2‑agonists and are usually mild, but clinicians should remain aware of less common serious events.

Common

• Headache – mild to moderate intensity, often transient.
• Throat irritation – sensation of dryness or mild soreness.
• Cough – non‑productive and usually resolves with continued use.
• Dry mouth – reduced salivation, often mild and transient.
• Hypokalemia – low blood potassium levels that may cause muscle weakness or cardiac effects.

Serious

• Paradoxical bronchospasm – sudden worsening of breathing difficulty.
• Significant tachycardia or arrhythmia – rapid heart rate or irregular rhythm requiring medical attention.
• Severe allergic reaction – includes angioedema, swelling, or anaphylaxis.

When prescribing Hirobriz Breezhaler, healthcare professionals should consider several precautionary measures to ensure safe use.

• Confirm COPD diagnosis and assess severity before initiating therapy.
• Evaluate for a history of cardiovascular disease, especially arrhythmias or recent myocardial infarction.
• Use caution in patients with known hypersensitivity to indacaterol or other β2‑agonists.
• Monitor lung function regularly to detect any unexpected decline.
• Educate patients on proper inhaler technique to avoid suboptimal dosing.
• Avoid abrupt discontinuation; assess need for continued therapy and adherence during regular follow‑up.

Hirobriz Breezhaler may interact with other medicines that affect β2‑adrenergic pathways or cardiac function, requiring careful review of a patient’s medication list.

Avoid

• Concurrent use with non‑selective β‑blockers, which can diminish bronchodilator effect.
• Combination with other long‑acting β2‑agonists, as this may increase risk of cardiovascular side effects.
• Use with caution in patients receiving theophylline, as additive bronchodilation may increase risk of tremor.

Use with caution

• Beta‑agonist containing inhaled corticosteroid combinations; monitor for additive tachycardia.
• Diuretics or other agents that may lower serum potassium; watch for hypokalemia.
• Monoamine oxidase inhibitors or tricyclic antidepressants; observe for possible arrhythmias.
• Concurrent use with antihistamines may cause mild sedation; monitor patient response.